Cargando…

Immunotherapy of melanoma

The immunotherapy is currently changing the landscape of oncology. Nowadays the standard of care in metastatic or unresectable melanoma patients include immunomodulating modalities such as anti-PD-1 drugs (nivolumab, pembrolizumab) and anti-CTLA-4 antibody ipilimumab. The improvements of progression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lugowska, Iwona, Teterycz, Pawel, Rutkowski, Piotr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2018
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885078/ https://www.ncbi.nlm.nih.gov/pubmed/29628796 http://dx.doi.org/10.5114/wo.2018.73889

Ejemplares similares

Comparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage
por: Teterycz, Pawel, et al.
Publicado: (2019)

Follow-up in melanoma patients
por: Rutkowski, Piotr, et al.
Publicado: (2014)

IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma
por: Lugowska, Iwona, et al.
Publicado: (2018)

Mutation profile of primary subungual melanomas in Caucasians
por: Borkowska, Aneta, et al.
Publicado: (2020)

Trametinib: a MEK inhibitor for management of metastatic melanoma
por: Lugowska, Iwona, et al.
Publicado: (2015)

Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study
por: Rutkowski, Piotr, et al.
Publicado: (2020)

Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy
por: Teterycz, Pawel, et al.
Publicado: (2020)

Follow-up in soft tissue sarcomas
por: Rutkowski, Piotr, et al.
Publicado: (2014)

Long-term follow-up in adults with extremity osteosarcoma: comparison of different surgical procedures – single-center experience
por: Goryń, Tomasz, et al.
Publicado: (2019)

The Long-Term Outcomes of Intensive Combined Therapy of Adult Patients with Localised Synovial Sarcoma
por: Kozak, Katarzyna, et al.
Publicado: (2020)

Serum markers in early-stage and locally advanced melanoma
por: Lugowska, Iwona, et al.
Publicado: (2015)

Clinicopathological Features and Prognostic Factors of Primary Acral Melanomas in Caucasians
por: Borkowska, Aneta M., et al.
Publicado: (2020)

Genetic polymorphisms may influence the vertical growth rate of melanoma
por: Sikora, Mariusz, et al.
Publicado: (2018)

Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors
por: Kamińska-Winciorek, Grażyna, et al.
Publicado: (2019)

BRAF inhibition curtails IFN‐gamma‐inducible PD‐L1 expression and upregulates the immunoregulatory protein galectin‐1 in melanoma cells
por: Górniak, Patryk, et al.
Publicado: (2020)

Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre study
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2019)

The Analysis of Trends in Survival for Patients with Melanoma Brain Metastases with Introduction of Novel Therapeutic Options before the Era of Combined Immunotherapy—Multicenter Italian–Polish Report
por: Placzke, Joanna, et al.
Publicado: (2022)

Stereotactic radiotherapy for soft tissue and bone sarcomas: real-world evidence
por: Spałek, Mateusz Jacek, et al.
Publicado: (2022)

Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma
por: Dawidowska, Anna, et al.
Publicado: (2022)

Treatment of Metastatic Gastrointestinal Stromal Tumors (GIST): A Focus on Older Patients
por: Dudzisz-Śledź, Monika, et al.
Publicado: (2021)

Plasma lncRNA expression profile as a prognostic tool in BRAF-mutant metastatic melanoma patients treated with BRAF inhibitor
por: Kolenda, Tomasz, et al.
Publicado: (2019)

Myocarditis Induced by Immunotherapy in Metastatic Melanoma—Review of Literature and Current Guidelines
por: Czarnecka, Anna M., et al.
Publicado: (2022)

Triple combinations of immunotherapy and targeted therapy in patients with melanoma with brain metastases
por: Rutkowski, Piotr, et al.
Publicado: (2023)

The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*
por: Rutkowski, Piotr, et al.
Publicado: (2017)

Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF (V600) Mutation-Positive Melanoma
por: Czarnecka, Anna M., et al.
Publicado: (2021)

Efficacy and Safety of Hypofractionated Preoperative Radiotherapy for Primary Locally Advanced Soft Tissue Sarcomas of Limbs or Trunk Wall
por: Koseła-Paterczyk, Hanna, et al.
Publicado: (2021)

Mutational landscape of primary and recurrent Ewing sarcoma
por: Jagodzińska-Mucha, Paulina, et al.
Publicado: (2021)

Functional outcome of surgical treatment of adults with extremity osteosarcoma after megaprosthetic reconstruction—single-center experience
por: Goryń, Tomasz, et al.
Publicado: (2019)

Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis
por: Wiater, Katarzyna, et al.
Publicado: (2013)

Systemic Treatment for Advanced and Metastatic Malignant Peripheral Nerve Sheath Tumors—A Sarcoma Reference Center Experience
por: Sobczuk, Paweł, et al.
Publicado: (2020)

Acral lentiginous melanoma histotype predicts outcome in clinical stage I-II melanoma patients: an International multicenter study
por: Mandalà, M., et al.
Publicado: (2022)

Gene expression profiling of peripheral blood cells: new insights into Ewing sarcoma biology and clinical applications
por: Przybyl, Joanna, et al.
Publicado: (2014)

Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2013)

The greatest achievements in oncology in 2022 – melanoma and skin carcinomas
por: Rutkowski, Piotr
Publicado: (2022)

The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial
por: Rutkowski, Piotr, et al.
Publicado: (2015)

Efficacy of Sirolimus Treatment in PEComa–10 Years of Practice Perspective
por: Świtaj, Tomasz, et al.
Publicado: (2021)

Melanoma Mortality Trends in 28 European Countries: A Retrospective Analysis for the Years 1960–2020
por: Koczkodaj, Paweł, et al.
Publicado: (2023)

Beyond PD-1 Immunotherapy in Malignant Melanoma
por: Kwiatkowska, Dominika, et al.
Publicado: (2019)

Immunotherapy of melanoma
por: Haanen, John B.A.G.
Publicado: (2013)

Melanoma immunotherapy
por: Garg, Abhishek D., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7cajk34rpmiv8n7394l6vrjqtn